30th Jun 2015 11:56
LONDON (Alliance News) - Ergomed PLC on Tuesday said co-development partner Aeterna Zentaris has completed recruiting patients for its Phase 3 Zoptarelin Doxorubicin in Endometrial Cancer study.
The study will examine the effects of giving women with advanced, recurring or metastatic endometrial cancer zoptarelin doxorubicin.
"We believe that zoptarelin doxorubicin has the potential to provide a new treatment for women with endometrial cancer, and look forward to obtaining data and progressing this study with our co-development partner Aeterna Zentaris, who are also advancing their plans for the commercialisation of this product," said Ergomed Chief Executive Miroslav Reljanovic.
Ergomed shares were untraded Tuesday, having last traded at 174.80 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ERGO.L